The Health Commission of Congress gave the green light last week to one of the most relevant modifications in recent years regarding pharmaceutical policy. Taking advantage of the processing of the bill on neonatal screening, the parliamentary groups of the PSOE, Sumar, and Partido Popular agreed to incorporate an amendment...
More than fifty organizations have urged the European Parliament to take advantage of the negotiation of the EU's next research program to introduce requirements that guarantee that medicines, vaccines, and other health tools financed with public money effectively reach the people who need them.Among the 54 signatory organizations are Health...
The National Association of Health Informers (ANIS) and the Spanish Association of Orphan and Ultra-Orphan Drug Laboratories (AELMHU) held a new edition of their Training Day for Journalists this Thursday, dedicated to rare diseases and orphan drugs. At the opening of the meeting, Beatriz Perales, president of AELMHU, presented the current...
The Assembly of the Spanish Association of Laboratories of Orphan and Ultra-Orphan Drugs (AELMHU), made up of its 29 associated companies, has elected this Wednesday the new Board of Directors of the Association for the 2026-2028 period. The AELMHU Board of Directors, which will continue to be chaired by Beatriz...
The Spanish Business Federation of Pharmacists (FEFE) has come out this Monday in defense of the Spanish pharmacy model, which it considers a key part of the healthcare network to ensure equity in access to medicines. Its position responds to the report by the National Commission on Markets and Competition...
The Spanish Confederation of Alzheimer's and other Dementias (CEAFA) held this morning in the Manuel Giménez Hall of the Senate the conference "Redefining the gaze towards Alzheimer's. Search for answers for patients in early stages" The meeting brought together health professionals, representatives from the social sphere, affected individuals, and political...
Question: Let's start by talking about the amendments that insist on protecting incentives for innovation and economic viability of orphan drugs. Do you think the current European framework sufficiently guarantees that balance or that it needs to be strengthened?Answer: Responding very directly, I believe it is necessary to reinforce it,...
Last March, the European Parliament's SANT Committee approved both the directive and the regulation of the pharmaceutical legislative package, agreed on December 11 in the meetings between the European Commission, the Council, and the European Parliament, the well-known trilogues.The result of the vote was 29 votes in favor, three against,...